First Horizon Advisors Inc. Raises Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

First Horizon Advisors Inc. raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 460 shares of the company’s stock after purchasing an additional 26 shares during the quarter. First Horizon Advisors Inc.’s holdings in IDEXX Laboratories were worth $223,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Lindbrook Capital LLC increased its position in IDEXX Laboratories by 73.3% during the 1st quarter. Lindbrook Capital LLC now owns 52 shares of the company’s stock valued at $25,000 after purchasing an additional 22 shares during the period. TCI Wealth Advisors Inc. grew its position in shares of IDEXX Laboratories by 120.8% in the 1st quarter. TCI Wealth Advisors Inc. now owns 53 shares of the company’s stock worth $26,000 after buying an additional 29 shares during the period. Institutional & Family Asset Management LLC grew its position in shares of IDEXX Laboratories by 150.0% in the 4th quarter. Institutional & Family Asset Management LLC now owns 55 shares of the company’s stock worth $27,000 after buying an additional 33 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $30,000. Finally, CVA Family Office LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter worth about $32,000. 84.53% of the stock is currently owned by institutional investors and hedge funds.

In other IDEXX Laboratories news, Director Jonathan W. Ayers sold 9,460 shares of the company’s stock in a transaction dated Friday, May 28th. The shares were sold at an average price of $562.26, for a total transaction of $5,318,979.60. Following the transaction, the director now owns 644,701 shares in the company, valued at approximately $362,489,584.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jonathan W. Ayers sold 512 shares of the company’s stock in a transaction dated Monday, May 10th. The shares were sold at an average price of $541.02, for a total transaction of $277,002.24. Following the transaction, the director now owns 653,703 shares in the company, valued at approximately $353,666,397.06. The disclosure for this sale can be found here. Insiders have sold a total of 42,004 shares of company stock worth $23,130,605 in the last 90 days. Company insiders own 2.06% of the company’s stock.

Shares of IDEXX Laboratories stock opened at $580.53 on Friday. The company has a market cap of $49.51 billion, a PE ratio of 74.71, a price-to-earnings-growth ratio of 3.52 and a beta of 0.89. The stock has a 50-day moving average price of $536.30. IDEXX Laboratories, Inc. has a 1 year low of $294.17 and a 1 year high of $581.18. The company has a current ratio of 1.77, a quick ratio of 1.41 and a debt-to-equity ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 4th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.63. The company had revenue of $777.71 million for the quarter, compared to analysts’ expectations of $738.43 million. IDEXX Laboratories had a net margin of 23.59% and a return on equity of 131.51%. IDEXX Laboratories’s revenue was up 24.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.29 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 8.12 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on IDXX shares. Barclays upped their target price on shares of IDEXX Laboratories from $600.00 to $616.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 5th. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating and set a $519.00 target price on the stock. in a research report on Tuesday, April 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. IDEXX Laboratories has a consensus rating of “Buy” and an average price target of $482.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: How is the Producer Price Index calculated?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.